Nuevolution appoint Dr. Paul Scigalla as Chief Medical Officer on consultancy basis

Stockholm, 23 January 2018. Nuevolution AB (publ) (NUE.ST) today announced the appointment of professor Paul Scigalla MD, PhD as new advisor to support Nuevolution in the role as a Chief Medical Officer on a consultancy basis.

Dr. Scigalla, is a physician and medical researcher with more than 30 years of experience in clinical development across multiple therapeutic areas. As head of Clinical Research for nephrology, oncology and bone metabolism at Boehringer Mannheim GmbH, he was responsible for the preclinical and clinical development of erythropoietin and approval of ibandronate for the treatment osteoporosis and bone metastases. He later served as Head of Global Development Therapeutics and Executive Vice President at SUGEN, Inc., responsible for the clinical development of multiple receptor tyrosine kinase inhibitors, including sunitib (Sutent®) and as Vice President Research Oncology, Pharmacia/Pfizer Bedminster, New Jersey. Since August 2003, he has served as a consultant to several pharmaceutical companies in US, Japan and Europe. Dr Scigalla received his medical training from the University of Humboldt and was appointed Professor of Medicin from the University of Heidelberg in 1992.

Dr. Scigalla will support Nuevolution’s team with regards to planning and execution of pre-clinical and clinical development of Nuevolution’s own programs.

We are delighted to have Paul’s expertise to support the development of our preclinical and clinical programs” said, Thomas Franch, CSO of Nuevolution, and continued “Paul brings a tremendous experience in drug discovery and development across several therapeutic areas, which will help our current and future efforts in preclinical programs, regulatory activities and human clinical studies”.

Dr. Paul Scigalla commented “I am very excited about the company’s achievement and growing pipeline and I look forward to help progress interesting Nuevolution programs into clinical development”. 

For more information, please contact:

Thomas Franch, CSO

Phone: +45 7020 0922


Henrik D. Simonsen, CFO

Phone: +45 3913 0947


About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit for patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

The information was sent for publication, through the agency of the contact persons set out above, on Tuesday 23January 2018, 11:00 CET.

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Redeye AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found at:


About Us

Nuevolution is a biotechnology company with a unique business model, where continuous revenue generation and risk mitigation represent primary objectives. This strategy is executed by a “multiple shots at goal” approach in combination with reduced research costs, where simultaneous development of multiple programs in parallel is made possible. Nuevolution is the inventor of Chemetics®. Chemetics® is a patent protected drug discovery research platform, which enables identification of small molecule (tablet based) drug candidates much more effectively and at lower cost than what is possible by other conventional methods. Nuevolution applies its research platform for the identification and development of its own pipeline of drug candidates for treatment of cancer and chronic inflammatory diseases Nuevolution applies a business model that is unique for a biotechnology company with a primary focus on revenue generation and risk minimization (i.e. lower cost development) by having a number of programs developed in parallel. Nuevolution is the inventor of Chemetics® , a patent protected drug discovery platform which enables efficient discovery of novel chemical small molecule leads for specific indications addressing disease targets within the company’s therapeutic focus areas


Documents & Links